EGFR UNCOMMON MUTATIONS, INCLUDING G719X AND S768I

Clinical trials for EGFR UNCOMMON MUTATIONS, INCLUDING G719X AND S768I explained in plain language.

Never miss a new study

Get alerted when new EGFR UNCOMMON MUTATIONS, INCLUDING G719X AND S768I trials appear

Sign up with your email to follow new studies for EGFR UNCOMMON MUTATIONS, INCLUDING G719X AND S768I, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New hope for tough-to-treat lung cancers as experimental drug enters human trials

Disease control Ongoing

This early-stage study is testing an experimental drug called furmonertinib for people with advanced lung cancer that has specific genetic mutations. The trial aims to find the safest and most effective dose while checking if the drug can shrink tumors. It involves 160 patients w…

Matched conditions: EGFR UNCOMMON MUTATIONS, INCLUDING G719X AND S768I

Phase: PHASE1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control

Last updated Mar 23, 2026 15:17 UTC

EGFR UNCOMMON MUTATIONS, INCLUDING G719X AND S768I

Get alerted when new EGFR UNCOMMON MUTATIONS, INCLUDING G719X AND S768I trials appear

New hope for tough-to-treat lung cancers as experimental drug enters human trials